



American Retina Forum 2026 National Meeting

Wednesday, August 5th – Saturday, August 8th
Margaritaville Resort, South Lake Tahoe, CA

No Suits...
No Podiums...
Shoes Optional.


EYEPOINT™ **Only Multi-MOA TKI in Phase 3 for Wet AMD and DME**

EYP-1901 combines vorolanib with Durasert E™ technology to deliver a continuous daily dose for at least 6 months.

Therapeutic levels of vorolanib reached within hours^a

Inhibition of VEGF receptors, PDGF and pro-inflammatory IL-6-mediated signaling^a

Consistent daily dosing with target inhibition for ≥6 months



Full elution of vorolanib before matrix bioerosion; no free-floating drug particles

No cold storage required; pre-loaded IVT syringe injector

EYP-1901 is an investigational product and the safety and efficacy of EYP-1901 has not been established. FDA has not approved EYP-1901 in the United States. The materials discussed do not predict future FDA approval. Conclusive evidence of efficacy and safety of EYP-1901 will require further investigation in well-controlled Phase 3 clinical trials. Insert not drawn to scale, for illustrative purposes only.

The investigational dose for phase 3 trials is 2.7mg (two inserts) administered with one injection. ^aData from preclinical studies. Following a single EYP-1901 900 µg dose in Dutch Belted rabbits, vorolanib reached concentrations exceeding IC₅₀ in the choroid and retina within hours of administration. IVT, intravitreal; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor; IL-6, interleukin-6.

EyePoint and the EyePoint logo are registered trademarks of EyePoint, Inc.

©2018-2026 EyePoint, Inc. All Rights Reserved

**ASK ABOUT OUR
TKI** 



Learn more at askaboutourtki.com



Welcome to the National Meeting of the American Retina Forum

Thank you all for joining us to discuss how we can better care for our patients and preserve their vision. The thoughtful, in-depth discussions that define this meeting are unlike those at most conferences, and we hope you leave with practical insights that will directly enhance your everyday practice.

We're also especially grateful to those who brought their families and loved ones. One of the greatest strengths of this community is the opportunity to get to know one another not only as colleagues, but as people.

We hope you enjoy the meeting and your time together.

Cheers,

H.K. PANDYA, MD

Hemang K. Pandya MD
President
American Retina Forum

Mitul C. Mehta MD MS
Vice President
American Retina Forum



Pictured Above: Group photo from National Meeting of the American Retina Forum in 2024 in Carlsbad, California.

Presenters:

Sean Adrean, MD
Fullerton, CA

Ramsudha Narala, MD
Palo Alto, CA

Radwan Ajlan MB BCh FRCS(C), FICO, DABO, FASRS
Kansas City, KS

Zackery Oakey, MD
Irvine, CA

David RP Almeida MD, MBA, PhD, DABO, FRCSC, FASRS
Erie, PA

Hemang K. Pandya, MD FACS
Plano, TX

Alexander Barash, MD
New York, NY

Aryeh Pollack, MD
New York, NY

Steven M. Christiansen, MD
Castle Rock, CO

Michael Rafalof, MD
Irvine, CA

Jonathan Feistmann, MD
New York, NY

Larry Puthenparambil, MD
Houston, TX

Vivienne S. Hau, MD PhD
Riverside, CA

Mohammad Riazi Esfahani, MD
Irvine, CA

Henry Holt MD
Wilmington, NC

Beth Richter, MD PhD
Sarasota, FL

Nora Khatib, MD
San Diego, CA

Nathan Rudometkin, MD
Laguna Woods, CA

Carissa Klaas, OD MD FASRS
Indianapolis, IN

Ajay Singh, MD
Independence, MO

Albert Lin, MD
Jackson, MS

Jessica Weinstein, MD
Spokane, WA

Stuart J. McFarland MD
Jackson, MS

Sarwar Zahid, MD
Palo Alto, CA

Scientific Program

CME Accreditation statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Ophthalmology and the American Retina Forum. The American Academy of Ophthalmology is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The American Academy of Ophthalmology designates this live activity for a maximum of 9.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives

Identify:

- malignant tumors of the eye and know when to refer for a higher level of care
- idiopathic macular telangiectasis and know how to treat it,
- risks for complications in retinal surgery and know how to repair them
- best practices in the management of tractional retinal detachment due to diabetic retinopathy
- reasons for the lack of women in the field of retina and help address the issue

Learn how to:

- perform clinical trials
- start a solo practice
- set up and identify patients suited for office based retinal surgery
- utilize artificial intelligence in retina practice
- procure medications used to treat retinal diseases,
- integrate refractive cataract surgery in a retina practice
- screen for retinal complications from systemic medications

Discuss modern techniques for closing and managing macular holes, treatment and counseling of patients for wet and dry AMD, & treatment of diabetic retinopathy

Discuss management of ocular trauma & complex surgical diseases of the retina

The following faculty have reported relevant financial relationships:

Sean Adrean, MD

4DMT: Grant Support
Adverum: Consultant, stock in a public company, grant support
Alcon Labs: Consultant
Amgen: Grant Support
Annexon: Grant Support
Appellis Pharma: Speaker's bureau, grant support
EyePoint: Grant support
Genentech: Consultant, Grant Support
Janssen Pharma: Grant Support
Kodiak Life Sciences: Grant Support
Novartis Pharma AG: Grant Support
Ocular Therapeutics: Grant Support
Opthea US Limited: Grant Support, Consultant
Priovent: Grant Support
Regeneron Pharmaceuticals: Grant Support
RegenXBio: Grant Support, Consultant
Rezolute: Grant Support

David Almeida, MD

Acelyrin: Consultant, Lecture Fees
Alcon Labs: Consultant, Lecture Fees
Alimera Sciences: Consultant, Lecture Fees
Allergan: Consultant, Lecture Fees
Bausch & Lomb: Consultant

Bayer Healthcare Pharma: Consultant, Lecture Fees

Biogen MA Inc: Consultant

Carl Zeiss Meditec: Consultant, Lecture Fees
Citrus Therapeutics: Stock in a Private company, employee, grant support, patent
EyePoint Pharma: Consultant
Genentech Pharma: Consultant, Lecture Fees
Gyroscope Therapeutics: Consultant
Hoffman La Roche Ltd: Consultant, Lecture Fees
Novartis Pharma AG: Consultant, Lecture Fees
Ocugen: Consultant
Regeneron Pharma: Consultant, Lecture Fees

Alexander Barash, MD
Optovue: Consultant

Steve Christiansen, MD
Aseptikits: Speaker's bureau

Jonathan Feistmann, MD
Carl Zeiss Meditec: Consultant

Vivienne Hau, MD
4DMT: Grant Support
Abbvie: Grant Support

Adverum: Grant Support

Genentech: Grant Support

Regeneron Pharma: Grant Support

Regenxbio: Grant Support

Henry Holt, MD

Inflammasome Therapeutics: Stock in a public company

Zackery Oakey, MD

Immunocore: Consultant

Beth Richter, MD

Astellas: Independent Contractor

Ajay Singh, MD

Abbvie: Speaker's bureau

Sarwar Zahid, MD

Abbvie: Independent Contractor

Alcon Laboratories: consultant

Allergan Inc.: Independent Contractor

Eyepoint: Independent Contractor

Heidelberg Engineering: Independent Contractor

Regeneron Pharmaceuticals: Independent Contractor

All other staff, faculty and planners report no relevant financial relationships.

All relevant financial relationships have been mitigated.

Scientific Program

Wednesday, August 5th, 2026

7:00 PM Welcome

Thursday, August 6th, 2026

8:00 AM Ocular Oncology *Zack Oakey, MD & Ramsudha Narala, MD*

8:30 AM Macular Hole *Alex Barash, MD*

9:00 AM MacTel and Photobiomodulation for Geographic Atrophy *Zack Oakey, MD*

9:30 AM Craziest Case *Henry Holt, MD*

10:00 AM Break

10:30 AM Complications *Radwan Ajlan, MD & Michael Rafaelof, MD*

11:00 AM Wet AMD *Ajay Singh, MD*

11:30 AM Dry AMD Hemang Pandya, MD

1:00 PM-5:00 PM Poster Session- Garden Atrium

Friday, August 7th, 2026

8:00 AM DME/Diabetic Retinopathy Mohammad Riazi Esfahani, MD

8:30 AM Diabetic Tractional Retinal Detachment Repair *Aryeh Pollack, MD*

9:00 AM Pneumatic Retinopexy *Larry Puthenparambil, MD*

9:30 AM Retinal Detachment Repair *David Almeida, MD MBA PhD*

10:00 AM Break

10:30 AM Ocular Trauma *Albert Lin, MD & Stuart McFarland, MD*


11:00 AM Office based surgery *Jonathan Feistmann, MD*

11:30 AM Clinical trials workshop *Vivienne Hau, MD PhD, & Beth Richter, MD PhD*

1:00 PM - 5:00 PM Poster Session - Garden Atrium

5:00-6:00PM Q & A with Poster Authors

7:00 PM Award Ceremony




Scientific Program

Saturday, August 8th, 2026

- 8:00 AM Lack of Women in Retina - is there a bias or is it personal preference?
Vivienne Hau, MD PhD, Beth Richter, MD PhD, & Jessica Weinstein, MD
- 8:30 AM AI in Retina Practice *Nathan Rudometkin, MD*
- 9:00 AM Advocacy *Sarwar Zahid, MD*
- 9:15 AM GA & CNV *Sean Adrean, MD*
- 9:30 AM Uveitis *Jessica Weinstein, MD*
- 10:00 AM Break
- 10:30 AM Retinal Screening for Systemic Medications *Carissa Klaas, MD*
- 11:00 AM Integrating Refractive Cataract Surgery in a Retina Practice *Nora Khatib, MD*
- 11:30 AM Bevacizumab Compounding in Retina Practice *Steve Christiansen, MD*
- 12:00 PM How to Start a Solo Practice *Nadeem Vaidya, MD*
- 7:00 PM Farewell

Poster Presentations- Garden Atrium

- 1 Pneumatic Retinopexy using a 6mm Needle.
Nairi Rostomian, Dan Kamen, & Jerome Giovinazzo
- 2 Predicting Anti-VEGF Treatment Response in Diabetic Macular Edema Using Automated OCT Biomarkers
Peter W. Clark, MD
- 3 Blue Light-Induced Toxic Maculopathy Following High-Intensity Flashlight Exposure
Keenan Downs, Henry Tang, and Hardeep Dhindsa, MD
- 4 Why Ophthalmic Gene and Cell Therapies Fail: A Survey of U.S. Pipeline Discontinuations
Serena Zhao, William Cheong, Eric L. Wan, MPH, MBA, Vivienne Hau, MD, PhD



THANK YOU to the following sponsors for their generous support:

Diamond

Astellas

EyePoint

Platinum

Genentech

Gold

AbbVie

Adverum

Alcon

Bausch + Lomb

Biogen

Harrow, Inc.

Neurotech

Norlase

Optos

Prima Medical

Regeneron

Topcon

Zeiss

Startup Sponsor

Adaptive Sensory
Technology



IT'S NOT JUST DATA
IT'S REAL-WORLD RESULTS



SCAN TO
EXPLORE FARETINA

Genentech
A Member of the Roche Group

**CHOOSE
VABYSMO®
FIRST**